In a significant legal development, a Delaware federal judge has reaffirmed a jury verdict that mandates Guardant Health Inc. to pay $83.4 million to TwinStrand Biosciences Inc. for patent infringement related to diagnostic technologies. This decision, delivered on Tuesday, maintains that the violation was willful and thus upholds the substantial jury award initially rendered in 2023. The [jury’s decision](https://www.law360.com/ip/articles/2490437?utm_source=rss&utm_medium=rss&utm_campaign=section) underscores the increasingly high stakes in intellectual property litigation within the biotech sector.
Guardant Health, a prominent player in cancer diagnostics, faced allegations from TwinStrand Biosciences that it had unlawfully utilized patented technology designed to enhance the accuracy of DNA sequencing in cancer detection processes. The jury sided decisively with TwinStrand, concluding that the infringement was not only present but carried out with full awareness of the patent rights.
Efforts by Guardant Health to either overturn or seek a reduction of the awarded damages were rebuffed by the judge, emphasizing the integrity of the jury’s findings. Legal experts have noted that the decision reflects a broader trend of uncompromising enforcement of IP rights in the biotechnology field, which often involves critical innovations with high research and development investments.
As reported by [Bloomberg Law](https://news.bloomberglaw.com/ip-law/guardant-fails-to-overturn-83-4-million-ip-verdict-in-delaware), the case not only highlights the judicial system’s stance on protecting patent holders but also serves as a cautionary tale for companies operating in the competitive landscape of medical technology. The ruling may deter companies from engaging in practices that flirt with intellectual property boundaries.
Industry observers are closely watching the ramifications of this decision as it could shape future patent disputes and litigation strategies. For now, TwinStrand Biosciences’ substantial award marks a pivotal victory in the defense of its innovative contributions to cancer diagnostics.